Pfizer Corporation

Will Somers

Leo J Letendre

Tao He

Wenge Wang

Amarnauth Shastrie Prashad

Xiaotian Zhong

Ronald William Kriz

Leo Joseph Letendre

An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.

Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation

Growing community of inventors

Lexington, MA, United States of America

Will Somers